



Michele Uda

DIRECTOR GENERAL at EGUALIA – Industrie Farmaci Accessibili

Italian association for accessible medicines, official representative body of the generic, biosimilar and value added medicines in Italy

MEMBER of the Executive Committee of Medicines for Europe

CHAIRMAN of the NAC (National Association Committee of Medicines for Europe)

Graduated in Political Science from the International University LUISS Guido Carli in Rome, with a specialization in International Economics, after an initial experience in one of the largest Italian trade unions, he has successfully completed a full time MBA in International Business and Economics at "Mib School of Management" of Trieste. He then continued his career in the retail consumer sector at Ferrero Italy as Assistant Brand Manager for the Italian multinational company's core business and, later, at Colgate Palmolive Italy as a market and industry sales analyst in the Household Care division. He stepped into the healthcare sector joining Johnson & Johnson Medical where he was responsible for direct management of sales and marketing for the breast care line in Italy's central and southern regions.

From March 2007 he joined EGUALIA (formerly known as Assogenerici, the Italian Generic and Biosimilar Medicines Association), as "Pharmaceutical Economics & Policy Affairs Manager", assuming direct responsibility of the Centre for Economics and Policy Analysis of the association.

From April 2012 he has been appointed Director General of EGUALIA, keeping also the responsibility for international relations. Since 2014 is also managing IBG – Italian Biosimilars Group, representing the biosimilar medicines industry within EGUALIA and more recently the VAM – Value Added Medicine Group of EGUALIA.

Member of the Executive Committee of Medicines for Europe (European Generic & Biosimilars Medicines Industry Association); appointed Chairman of the GMAC (Generic Market Access Committee of Medicines for Europe) in 2011, he is now Chairman of the NAC (National Association Committee of Medicines for Europe).

Updated – September 2021